111 related articles for article (PubMed ID: 19695230)
1. The ubiquitin-interacting motifs of S5a as a unique upstream inhibitor of the 26S proteasome.
Elangovan M; Shin DY; Yoo YJ
Biochem Biophys Res Commun; 2009 Oct; 388(4):723-6. PubMed ID: 19695230
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death.
Elangovan M; Choi ES; Jang BG; Kim MS; Yoo YJ
Biochem Biophys Res Commun; 2007 Dec; 364(2):226-30. PubMed ID: 17949686
[TBL] [Abstract][Full Text] [Related]
3. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
[TBL] [Abstract][Full Text] [Related]
4. VWA domain of S5a restricts the ability to bind ubiquitin and Ubl to the 26S proteasome.
Piterman R; Braunstein I; Isakov E; Ziv T; Navon A; Cohen S; Stanhill A
Mol Biol Cell; 2014 Dec; 25(25):3988-98. PubMed ID: 25318673
[TBL] [Abstract][Full Text] [Related]
5. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition.
Uchiki T; Kim HT; Zhai B; Gygi SP; Johnston JA; O'Bryan JP; Goldberg AL
J Biol Chem; 2009 May; 284(19):12622-32. PubMed ID: 19240029
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin receptors play redundant roles in the proteasomal degradation of the p53 repressor MDM2.
Sparks A; Kelly CJ; Saville MK
FEBS Lett; 2022 Nov; 596(21):2746-2767. PubMed ID: 35735670
[TBL] [Abstract][Full Text] [Related]
7. Structure of the s5a:k48-linked diubiquitin complex and its interactions with rpn13.
Zhang N; Wang Q; Ehlinger A; Randles L; Lary JW; Kang Y; Haririnia A; Storaska AJ; Cole JL; Fushman D; Walters KJ
Mol Cell; 2009 Aug; 35(3):280-90. PubMed ID: 19683493
[TBL] [Abstract][Full Text] [Related]
8. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of the E3 ligase parkin with the proteasomal subunit S5a and the endocytic protein Eps15.
Safadi SS; Shaw GS
J Biol Chem; 2010 Jan; 285(2):1424-34. PubMed ID: 19875440
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-independent degradation of proteins by the proteasome.
Jariel-Encontre I; Bossis G; Piechaczyk M
Biochim Biophys Acta; 2008 Dec; 1786(2):153-77. PubMed ID: 18558098
[TBL] [Abstract][Full Text] [Related]
11. S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains.
Kim HT; Kim KP; Uchiki T; Gygi SP; Goldberg AL
EMBO J; 2009 Jul; 28(13):1867-77. PubMed ID: 19387488
[TBL] [Abstract][Full Text] [Related]
12. Functional differences between two major ubiquitin receptors in the proteasome; S5a and hRpn13.
Elangovan M; Oh C; Sukumaran L; Wójcik C; Yoo YJ
Biochem Biophys Res Commun; 2010 May; 396(2):425-8. PubMed ID: 20417181
[TBL] [Abstract][Full Text] [Related]
13. Degradation of Intrinsically Disordered Proteins by the NADH 26S Proteasome.
Tsvetkov P; Myers N; Adler J; Shaul Y
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33297334
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
15. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
[TBL] [Abstract][Full Text] [Related]
16. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.
Liu J; Zheng H; Tang M; Ryu YC; Wang X
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2541-50. PubMed ID: 18978187
[TBL] [Abstract][Full Text] [Related]
17. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.
Herrmann JL; Briones F; Brisbay S; Logothetis CJ; McDonnell TJ
Oncogene; 1998 Dec; 17(22):2889-99. PubMed ID: 9879995
[TBL] [Abstract][Full Text] [Related]
18. Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?
Salvat C; Aquaviva C; Jariel-Encontre I; Ferrara P; Pariat M; Steff AM; Carillo S; Piechaczyk M
Mol Biol Rep; 1999 Apr; 26(1-2):45-51. PubMed ID: 10363646
[TBL] [Abstract][Full Text] [Related]
19. Structure of S5a bound to monoubiquitin provides a model for polyubiquitin recognition.
Wang Q; Young P; Walters KJ
J Mol Biol; 2005 May; 348(3):727-39. PubMed ID: 15826667
[TBL] [Abstract][Full Text] [Related]
20. Interaction of HPV E6 oncoproteins with specific proteasomal subunits.
Tomaić V; Ganti K; Pim D; Bauer C; Blattner C; Banks L
Virology; 2013 Nov; 446(1-2):389-96. PubMed ID: 24074603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
